- Home
- MVST vs FENC Comparison
MVST vs FENC Comparison
Compare MVST & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$1.61
HOLD
Current Price
$7.34
Company Overview
Basic Information| Metric | MVST | FENC |
|---|---|---|
| Founded | 2006 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 987.8M | 266.4M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | MVST | FENC |
|---|---|---|
| Price | $1.61 | $7.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $6.00 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 4.5M | 120.6K |
| Earning Date | 03-16-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 96.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $47,538,000.00 |
| Revenue This Year | $29.85 | N/A |
| Revenue Next Year | $36.59 | $70.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 123.69 |
| 52 Week Low | $1.09 | $4.68 |
| 52 Week High | $7.12 | $9.92 |
Technical Indicators
Market Signals| Indicator | MVST | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 33.65 | 41.25 |
| Support Level | N/A | $7.44 |
| Resistance Level | $3.78 | $8.19 |
| Average True Range (ATR) | 0.15 | 0.43 |
| MACD | -0.04 | -0.07 |
| Stochastic Oscillator | 8.02 | 11.79 |
Price Performance
Historical Comparison MVST
FENC
About MVST Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extends from core battery chemistry to battery packs.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.